SCHEMBL1747386

SCHEMBL1747386

COC(=O)CCc1ccc(OCc2ccc(CSc3nc(-c4ccccc4)cs3)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
MCL1 Q07820 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
FFAR1 O14842 8/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
FFAR4 Q5NUL3 3/20 0.45
VDR P11473 2/20 0.44
PPARD Q03181 1/20 0.44
APP P05067 1/20 0.44
PLAU P00749 1/20 0.44
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
AKR1B1 P15121 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745596 0.90 FFAR1 (0.60) TP53TSHRMCL1L3MBTL1FFAR1
SCHEMBL1745242 0.83 MAPT (0.52) FFAR1NPC1RAB9AMEN1KMT2A
SCHEMBL1746563 0.81 KMT2A (0.49) L3MBTL1FFAR1MEN1KMT2AFFAR4
SCHEMBL1745444 0.80 KMT2A (0.48) L3MBTL1FFAR1MEN1KMT2AVDR
SCHEMBL3917024 0.80 NPSR1 (0.53) L3MBTL1FFAR1MEN1KMT2AFFAR4
SCHEMBL1745483 0.79 BCHE (0.51) FFAR1MEN1KMT2AVDRPPARD
SCHEMBL1747402 0.79 FFAR1 (0.48) L3MBTL1FFAR1MEN1KMT2AFFAR4
SCHEMBL1744673 0.79 FFAR1 (0.74) FFAR1FFAR4AKR1B1
SCHEMBL1745481 0.78 NPSR1 (0.47) L3MBTL1FFAR1MEN1KMT2AVDR
SCHEMBL1745485 0.78 FFAR1 (0.53) FFAR1FFAR4VDRPPARDAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR TP53 3714/4885TSHR 128/4885MCL1 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.